Feasibility of a blended therapy approach in the treatment of patients with inflammatory myopathies

Table 2 Demographic and clinical characteristics of the participants (N: 14)

Participant	Age	Sex	BMI	Diagnosis	Years since diagnosis	Physical activity	Medication
1	72	male	24	PM	4	active	steroid/immunosuppressive
2	40	male	28	DM	2	partially active	steroid
3	54	female	22	PM	28	inactive	steroid
4	56	female	22	DM	0.3	inactive	immunosuppressive/anti-malarial
5	60	male	23	DM	2	active	biologic agents
6	74	female	19	Statin-induced Myositis	7	active	biologic agents/immunosuppressive
7	55	male	17	PM	7	active	steroid/immunosuppressive
8	49	male	21	PM	7	active	steroid
9^a	64	female	35	DM	13	partially active	steroid
10	65	female	23	Overlap Syndrome	5	partially active	–
11	57	female	35	Associated Myositis	7	partially active	steroid/immunosuppressive
12	71	female	28	Associated Myositis	6	active	steroid
13	54	male	27	DM	14	trained	anti-malarial
14	51	male	30	Anti Synthetase Syndrome	3	inactive	steroid/immunosuppressive
Total Mean (SD)	59 (10)	7 male 7 female	25 (5)	4 PM 5 DM 5 other	7.5 (6.6)	6 active 4 partially active 3 inactive 1 trained

Legend: ^a: dropout, BMI body mass index, PM polymyositis, DM dermatomyositis, SD standard deviation, trained: vigorous intensity activities at least three days per week, active: recommended amount of physical activity per week (150 min of moderate intense activity), partially active: certain activities but does not meet the recommended amount of physical activity per week, inactive: less than half an hour per week

ISSN: 2057-0082